Trial Profile
A Multicenter, Open-Label Study to Evaluate the Safety and Tolerability of Intravenous Brivaracetam as Replacement for Oral Brivaracetam in Japanese Subjects ≥16 Years of Age With Partial Seizures With or Without Secondary Generalization
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 14 Apr 2022
Price :
$35
*
At a glance
- Drugs Brivaracetam (Primary)
- Indications Partial epilepsies
- Focus Adverse reactions; Registrational
- Sponsors UCB Biopharma
- 12 Apr 2021 Status changed from recruiting to completed.
- 03 Nov 2020 Planned End Date changed from 1 Mar 2021 to 1 Apr 2021.
- 03 Nov 2020 Planned primary completion date changed from 1 Mar 2021 to 1 Apr 2021.